The mission of Emmaus Life Sciences is to improve the lives of people in need through the discovery, development and commercialization of innovative treatments and therapies. Our focus has been on rare and orphan diseases, such as sickle cell disease. We are now extending our efforts to include conditions and diseases affecting larger populations, such as diverticulosis.
Read MoreSickle cell disease (SCD) is a group of inherited red blood cell disorders that affects about 100,000 Americans. This disease is present in affected individuals at birth and causes the production of abnormal hemoglobin.
Read MoreCampaign spokesperson Solomon Wilcots will be joined by fellow NFL Veteran Antonio "Dayla" Brown, the Advancing Sickle Cell Advocacy Project (ASAP) and the Foundation for Sickle Cell Disease Research (FSCDR)
Read MoreNet Revenues Increase 128% Year-Over-Year, as FDA-Approved Treatment for Sickle Cell Disease Rolls Out
Read MoreCompany to Announce Second Quarter Financial Results Next Week
Read MoreCompany to Appeal Nasdaq Staff’s Determination
Read MoreCampaign spokesperson Solomon Wilcots and Senior Vice President of Research and Development for Emmaus, Charles Stark, Pharm.D., will lead an informative presentation at the event’s Young Adult Reception.
Read MoreEmmaus to Appeal Nasdaq Staff’s Determination
Read MoreEmmaus Shares Expected to Begin Trading Tomorrow on Nasdaq Under Ticker Symbol “EMMA”
Read MoreThe proposed merger and spin-off transactions were approved by their respective stockholders at the special stockholder meetings held yesterday, July 9, 2019
Read MoreMerger and Spin-off Transaction on Track to Close by End of July New Spin-Off Record Date Set for July 15, 2019
Read MoreStudy will evaluate change in number and size of colonic diverticula and assess safety.
Read MoreEmmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the hiring of Michael Schwarz as its new Product Manager for Endari®
Read MoreEmmaus to use its pharmaceutical-grade L-glutamine ("PGLG") in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.
Read MoreEmmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC.
Read MoreTORRANCE, Calif., September 13, 2012 –In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.
Read MoreEmmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.
Read MoreEmmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
Read More